Nexelis, a provider of advanced assay development and laboratory testing services for infectious, oncologic, and metabolic diseases, has signed an asset purchase agreement with GlaxoSmithKline to acquire its GCLP-certified clinical bioanalytical lab in Marburg, Germany.


 
The Clinical Laboratory Science (CLS) team of approximately 80 scientists and analysts, will be transferred to Nexelis. The CLS team will support the development of future GSK vaccine candidates through a 5-year strategic collaboration agreement.


 
Nexelis plans to expand the Marburg site, initiating collaborations with other vaccine development companies as well as with the company’s other North American and European sites.


 
Nexelis expects to add new clinical testing platforms in Marburg that will be fully bridged with Laval platforms, develop synergies with its early development stage ImmunXperts branch in Belgium and leverage existing talents in fields such as biostatistics to form a broad-based, end-to-end service offering in bacteriology, virology, and oncology.
 
In the last three years, Nexelis also acquired Pacific Biomarkers, Seattle, WA; PAIRimmune, Laval, QC; ImmunXperts, Gosselies, BE; and AIT Bioscience, Indianapolis, IN.